-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Ginkgo Bioworks (NYSE:DNA) Trading 7.1% Higher
Ginkgo Bioworks (NYSE:DNA) Trading 7.1% Higher
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) traded up 7.1% during mid-day trading on Monday . The stock traded as high as $3.15 and last traded at $3.15. 827,671 shares traded hands during trading, a decline of 96% from the average session volume of 21,081,771 shares. The stock had previously closed at $2.94.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on the stock. Jefferies Financial Group cut their price objective on shares of Ginkgo Bioworks from $11.50 to $4.35 in a report on Thursday, June 16th. Raymond James increased their price target on shares of Ginkgo Bioworks from $11.50 to $14.50 and gave the company an "outperform" rating in a report on Tuesday, August 16th. Bank of America cut shares of Ginkgo Bioworks from a "neutral" rating to an "underperform" rating and set a $3.00 price target on the stock. in a report on Wednesday, May 18th. Finally, BTIG Research increased their price target on shares of Ginkgo Bioworks from $5.00 to $6.00 and gave the company a "buy" rating in a report on Tuesday, August 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $8.69.
Get Ginkgo Bioworks alerts:Ginkgo Bioworks Stock Up 7.8 %
The company has a market capitalization of $5.66 billion, a PE ratio of -1.62 and a beta of 1.84. The company's 50 day moving average is $2.96 and its two-hundred day moving average is $3.11. The company has a quick ratio of 11.78, a current ratio of 11.84 and a debt-to-equity ratio of 0.03.
Hedge Funds Weigh In On Ginkgo Bioworks
A number of institutional investors and hedge funds have recently made changes to their positions in DNA. B. Riley Wealth Management Inc. lifted its holdings in shares of Ginkgo Bioworks by 310.9% in the 2nd quarter. B. Riley Wealth Management Inc. now owns 48,900 shares of the company's stock worth $116,000 after acquiring an additional 37,000 shares during the last quarter. Amundi lifted its holdings in shares of Ginkgo Bioworks by 102.5% in the 2nd quarter. Amundi now owns 119,480 shares of the company's stock worth $369,000 after acquiring an additional 60,469 shares during the last quarter. Verition Fund Management LLC lifted its holdings in shares of Ginkgo Bioworks by 22.8% in the 2nd quarter. Verition Fund Management LLC now owns 47,361 shares of the company's stock worth $113,000 after acquiring an additional 8,780 shares during the last quarter. Legal & General Group Plc bought a new stake in shares of Ginkgo Bioworks in the 2nd quarter worth about $599,000. Finally, Centiva Capital LP bought a new stake in shares of Ginkgo Bioworks in the 2nd quarter worth about $99,000. 53.37% of the stock is owned by hedge funds and other institutional investors.About Ginkgo Bioworks
(Get Rating)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
See Also
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
- 3 Biotech Stocks Gaining Momentum
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) traded up 7.1% during mid-day trading on Monday . The stock traded as high as $3.15 and last traded at $3.15. 827,671 shares traded hands during trading, a decline of 96% from the average session volume of 21,081,771 shares. The stock had previously closed at $2.94.
银杏生物工程控股公司(纽约证券交易所代码：DNA-GET评级)周一午盘交易中上涨7.1%。该股一度涨至3.15美元，最后报3.15美元。827,671股股票在交易中成交，较21,081,771股的平均成交量下降96%。该股此前收盘价为2.94美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
A number of equities research analysts have weighed in on the stock. Jefferies Financial Group cut their price objective on shares of Ginkgo Bioworks from $11.50 to $4.35 in a report on Thursday, June 16th. Raymond James increased their price target on shares of Ginkgo Bioworks from $11.50 to $14.50 and gave the company an "outperform" rating in a report on Tuesday, August 16th. Bank of America cut shares of Ginkgo Bioworks from a "neutral" rating to an "underperform" rating and set a $3.00 price target on the stock. in a report on Wednesday, May 18th. Finally, BTIG Research increased their price target on shares of Ginkgo Bioworks from $5.00 to $6.00 and gave the company a "buy" rating in a report on Tuesday, August 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $8.69.
一些股票研究分析师对该股进行了加码。在6月16日星期四的一份报告中，杰富瑞金融集团将银杏生物的股票目标价从11.50美元下调至4.35美元。雷蒙德·詹姆斯在8月16日(星期二)的一份报告中将银杏生物工场的股票目标价从11.50美元上调至14.50美元，并给予该公司“跑赢大盘”的评级。美国银行将银杏生物的股票评级从“中性”下调至“表现不佳”，并为该股设定了3美元的目标价。在5月18日星期三的一份报告中。最后，BTIG Research在8月16日(星期二)的一份报告中将银杏生物工场的股票目标价从5.00美元上调至6.00美元，并给予该公司“买入”评级。一名投资分析师对该股的评级为卖出，一名分析师给出了持有评级，六名分析师给出了该公司股票的买入评级。根据MarketBeat.com的数据，该公司目前的平均评级为“中等买入”，平均目标价为8.69美元.
Ginkgo Bioworks Stock Up 7.8 %
银杏生物股份上涨7.8%
The company has a market capitalization of $5.66 billion, a PE ratio of -1.62 and a beta of 1.84. The company's 50 day moving average is $2.96 and its two-hundred day moving average is $3.11. The company has a quick ratio of 11.78, a current ratio of 11.84 and a debt-to-equity ratio of 0.03.
该公司市值为56.6亿美元，市盈率为-1.62，贝塔系数为1.84。该公司的50日移动均线切入位在2.96美元，200日移动均线切入位在3.11美元。该公司的速动比率为11.78，流动比率为11.84，债务权益比为0.03。
Hedge Funds Weigh In On Ginkgo Bioworks
对冲基金参与银杏生物工程
About Ginkgo Bioworks
关于银杏生物工场
(Get Rating)
(获取评级)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
银杏生物工程控股公司及其子公司开发细胞编程平台。它的平台用于对细胞进行编程，以实现产品的生物生产，如新型疗法、食品配料和从石油中提取的化学品。该公司服务于各种终端市场，包括特种化学品、农业、食品、消费品和药品。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
- 3 Biotech Stocks Gaining Momentum
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
- 免费获取StockNews.com关于银杏生物工程(DNA)的研究报告
- 3只被降级的必备股票放在你的观察名单上
- 这是对第三季度收益报告季节的预期
- 3只生物科技股势头强劲
- 电子艺界能扭转电子游戏市场的低迷吗？
- 美元将军是美国小池塘里的大鱼。
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
接受《银杏生物工场日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对银杏生物工程和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧